Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Study to Compare the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 With GW869682 in Subjects With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Remogliflozin etabonate (Primary) ; Sergliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 07 Oct 2006 New trial record.